These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12727114)

  • 1. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery.
    Schneider BL; Schwenter F; Pralong WF; Aebischer P
    Mol Ther; 2003 Apr; 7(4):506-14. PubMed ID: 12727114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts.
    Régulier E; Schneider BL; Déglon N; Beuzard Y; Aebischer P
    Gene Ther; 1998 Aug; 5(8):1014-22. PubMed ID: 10326023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A self-immunomodulating myoblast cell line for erythropoietin delivery.
    Schneider BL; Peduto G; Aebischer P
    Gene Ther; 2001 Jan; 8(1):58-66. PubMed ID: 11402302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression.
    Murua A; Orive G; Hernández RM; Pedraz JL
    J Control Release; 2009 Aug; 137(3):174-8. PubMed ID: 19376171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.
    Orive G; De Castro M; Ponce S; Hernández RM; Gascón AR; Bosch M; Alberch J; Pedraz JL
    Mol Ther; 2005 Aug; 12(2):283-9. PubMed ID: 15935736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression.
    Peduto G; Rinsch C; Schneider BL; Rolland E; Aebischer P
    Transplantation; 2000 Jul; 70(1):78-85. PubMed ID: 10919579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a composite drug delivery system to prolong functionality of cell-based scaffolds.
    Murua A; Herran E; Orive G; Igartua M; Blanco FJ; Pedraz JL; Hernández RM
    Int J Pharm; 2011 Apr; 407(1-2):142-50. PubMed ID: 21094235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia.
    Rinsch C; Dupraz P; Schneider BL; Déglon N; Maxwell PH; Ratcliffe PJ; Aebischer P
    Kidney Int; 2002 Oct; 62(4):1395-401. PubMed ID: 12234311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducing host acceptance to encapsulated xenogeneic myoblasts.
    Rinsch C; Peduto G; Schneider BL; Aebischer P
    Transplantation; 2001 Feb; 71(3):345-51. PubMed ID: 11233892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreservation based on freezing protocols for the long-term storage of microencapsulated myoblasts.
    Murua A; Orive G; Hernández RM; Pedraz JL
    Biomaterials; 2009 Jul; 30(20):3495-501. PubMed ID: 19327822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of erythropoietin delivery from engineered muscles in mice.
    Bohl D; Heard JM
    Hum Gene Ther; 1997 Jan; 8(2):195-204. PubMed ID: 9017423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts.
    Sommer B; Rinsch C; Payen E; Dalle B; Schneider B; Déglon N; Henri A; Beuzard Y; Aebischer P
    Mol Ther; 2002 Aug; 6(2):155-61. PubMed ID: 12161181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells.
    Lathuilière A; Cosson S; Lutolf MP; Schneider BL; Aebischer P
    Biomaterials; 2014 Jan; 35(2):779-91. PubMed ID: 24103654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts.
    Dalle B; Payen E; Regulier E; Deglon N; Rouyer-Fessard P; Beuzard Y; Aebischer P
    Gene Ther; 1999 Feb; 6(2):157-61. PubMed ID: 10435099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-L-lysine-alginate microcapsules.
    Murua A; de Castro M; Orive G; Hernandez RM; Pedraz JL
    Biomacromolecules; 2007 Nov; 8(11):3302-7. PubMed ID: 17941669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers.
    Pavlath GK; Rando TA; Blau HM
    J Cell Biol; 1994 Dec; 127(6 Pt 2):1923-32. PubMed ID: 7806570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells.
    Bose S; Volpatti LR; Thiono D; Yesilyurt V; McGladrigan C; Tang Y; Facklam A; Wang A; Jhunjhunwala S; Veiseh O; Hollister-Lock J; Bhattacharya C; Weir GC; Greiner DL; Langer R; Anderson DG
    Nat Biomed Eng; 2020 Aug; 4(8):814-826. PubMed ID: 32231313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent erythropoiesis by myoblast transfer of erythropoietin cDNA.
    Hamamori Y; Samal B; Tian J; Kedes L
    Hum Gene Ther; 1994 Nov; 5(11):1349-56. PubMed ID: 7893806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
    Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G
    J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
    Chanséaume S; Azarnoush K; Maurel A; Bellamy V; Peyrard S; Bruneval P; Hagège AA; Menasché P
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):293-7. PubMed ID: 17669846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.